The U.S. Food and Drug Administration (FDA) has approved application number ANDA086746 submitted by Lederle. The approval pertains to an oral tablet formulation of amitriptyline hydrochloride at a strength of 25 mg. The product is identified as "AMITRIPTYLINE HYDROCHLORIDE" with a product number 001 and is currently marked as discontinued.
The submission was classified as a supplemental (SUPPL) filing, submission number 2, with a status of AP (approved). It falls under the manufacturing (CMC) category, with the submission status date recorded as March 15, 1982.
No reference drug or reference standard was indicated for this product.
Actualizaciones regulatorias25 ago 2026•1 min de lectura
FDA Approves ANDA086746 for Amitriptyline Tablet – Lederle
1
FDA approved application ANDA086746 for an oral amitriptyline hydrochloride 25 mg tablet submitted by Lederle; the product is listed as discontinued.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración